Navigation Links
Selexis SA to Partner and Exhibit at BIO 2013
Date:4/10/2013

Geneva, Switzerland (PRWEB) April 10, 2013

Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today that representatives from the Company will be participating in the BIO International Convention’s One-on-One Partnering Meetings being held April 22 – 25, 2013 at McCormick Place in Chicago, IL.

Selexis has partnerships and commercial deals with leading biotechnology and pharmaceutical companies worldwide. Selexis’ SUREtechnology Platform™ offers a range of solutions for expressing genes in CHO cells and other mammalian systems and addresses issues such as over-expression of membrane proteins, secretion bottlenecks with difficult-to express proteins and development of high producing clonal cell lines for therapeutic protein programs. Selexis’ SUREtechnology Platform™ can be applied from early drug discovery to cGMP manufacturing, resulting in faster, more reliable, higher-expressing mammalian cell lines that can be applied to a wide range of areas such as diagnostics, drug discovery, therapeutics and bio-manufacturing.

Representatives will be available to discuss Selexis’ capabilities. Companies or individuals attending BIO 2013 can schedule meetings with Selexis by visiting (registration required): http://convention.bio.org/partner/

Selexis Business Forum Partnering Schedule:

  •     Monday, April 22    Business Forum - 08:00 AM – 05:00 PM
  •     Tuesday, April 23    Business Forum - 08:00 AM – 05:00 PM
  •     Wednesday, April 24    Business Forum - 08:00 AM – 05:00 PM
  •     Thursday, April 25    Business Forum - 08:00 AM – 12:00 PM

For companies or individuals not participating in partnering meetings, Selexis will be exhibiting in booth number #4158 located in Hall C

Selexis Exhibit Hall Schedule and Partnering:

  •     Monday, April 22    Hall C - 12:00 PM – 05:00 PM
  •     Tuesday, April 23    Hall C - 10:00 AM – 05:00 PM
  •     Wednesday, April 24    Hall C - 10:00 AM – 05:00 PM
  •     Thursday, April 25    Hall C - 10:00 AM – 12:00 PM

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,700 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.

For more information:

Read the full story at http://www.prweb.com/releases/2013_bio_conference/cell_line_development/prweb10611511.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Selexis SA to Present and Partner at the BIO-Europe Spring
2. Selexis SA Announces Publication in Metabolic Engineering of Data Demonstrating Improvement of Therapeutic Protein Secretion with Engineered CHO Cells
3. Healthy Vending Snacks Arrive to Philadelphia Rregion’s Most Honored and Respected Teaching Hospital; Thanks to Partnership with Award-Winning Food Services Provider
4. Team Red, White and Blue Enters Partnership with SteamVita to Support Combat Veterans and Families
5. BOMI International and Transwestern Partner to Offer Property and Facility Staff Skill-Enhancing Education Programs
6. Alliance Storage Technologies and Blue Chip Technical Services (Pvt) Ltd. Announce Partnership to Expand the Reach of Professional Data Archiving Solutions
7. ReviMedia Partners with RingRevenue to Deliver a Comprehensive Lead Generation Solution
8. The Signature Group, Inc. Partners with Alert Logic to Deliver Security and Compliance Solutions
9. Audiology Associates & Hearing Aids Today—Provider of Hearing Aids in Nashville TN—Released New Article for Coping Strategies for Partners
10. Doctors Spouses, Partners Say Theyre Satisfied
11. Brett A. Carter, Partner of Benson, Bertoldo, Baker & Carter, Received an AV Rating by Martindale-Hubbell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... The Dianne Michael ... headquartered in Hamilton County, is embarking on a charity drive with the aim ... new homes for orphaned or neglected senior dogs in the Cincinnati region, and ...
(Date:12/8/2016)... Goodyear, AZ (PRWEB) , ... December 08, 2016 ... ... planning firm with offices that serve communities in and around the greater Phoenix ... to the Homeless Youth Connection. , The mission of the Homeless Youth Connection ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Compretta Insurance Agency, a ... clients in and around the Hancock County area, is announcing the launch of a ... Pantry. , The Hancock County Food Pantry has worked for more than 30 years ...
(Date:12/8/2016)... KS (PRWEB) , ... December 08, 2016 , ... ... financial consultation services to families and business owners in and around central Kansas, ... provide assistance to at-risk youth in the region. , Headquartered in Wichita, Youth ...
(Date:12/7/2016)... Washington,DC (PRWEB) , ... December 07, 2016 , ... ... Forum (NYLF): Medicine will have the unique opportunity to get hands-on experience ... gives high school students an immersive experience to gain invaluable, real-life medical skills ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Dec. 8, 2016  The global biosurgery market is ... the forecast period of 2016 to 2021. The market ... from USD 18.21 billion in 2016. The market is ... of sports related injuries and spinal problems, increasing clearance ... of effective blood loss management. In this ...
(Date:12/8/2016)... -- KEY FINDINGS North America ... in 2016 and is expected to continue in the ... large number of surgical procedures that are taking place ... the patient temperature management market.) Patient warming and cooling ... blood during surgeries, lowering the risks of neurological disorders ...
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and Company ... of its phase 3 EXPEDITION3 trial at the 9 ... As previously disclosed, solanezumab did not meet the primary ... solanezumab initiated in people with mild dementia due to ... submissions for solanezumab for the treatment of mild dementia ...
Breaking Medicine Technology: